Imagine A World Without HIV

Addimmune^TM envisions a world without HIV. By harnessing the power of gene therapy, we believe we can achieve what was once thought impossible: a cure.

Addimmune^TM Technology

Addimmune to Go Public with 10X Capital Venture Acquisition Corp. III

Read The News Release Here - Aug 9th, 2023

Gene Therapy is the Future of Medicine

Our clinical milestones progress gives us confidence that we are on track for a potential HIV Cure. Using our unique technology we can actually put a little bit of DNA in each cell that reprograms it the way we want it to.

Watch How
Addimmune^TM Pursues a Cure
for HIV with Gene Therapy

Milestones Reached

HIV Cure Countdown

This HIV Cure Countdown outlines the critical milestones accomplished so far. We still have a few more to go, so follow along with us as we pursue a gene therapy cure for HIV.

HIV Cure Countdown

Addimmune Clinical Trial Progress

FEB - 2019
NIAID signs collaborative research agreement for HIV/AIDS cure strategy
MAY - 2019
HIV program granted a second patent for its unique molecule, methods, and cell process
APR - 2020
FDA granted Type-A meeting for HIV cure IND
AUG - 2020
FDA grants IND approval
OCT - 2020
HIV cure program Phase 1 begins (first patient enrolled)
NOV - 2020
HIV cure program second patient enrolled and first patient product complete

FEB - 2019
NIAID signs collaborative research agreement for HIV/AIDS cure strategy
MAY - 2019
HIV program granted a second patent for its unique molecule, methods, and cell process
APR - 2020
FDA granted Type-A meeting for HIV cure IND
AUG - 2020
FDA grants IND approval
OCT - 2020
HIV cure program Phase 1 begins (first patient enrolled)
NOV - 2020
HIV cure program second patient enrolled and first patient product complete